KalVista Pharmaceuticals, Inc. announced the initiation of the Phase III KONFIDENT clinical trial evaluating the efficacy and safety of KVD 900 as the first potential oral, on-demand therapy for hereditary angioedema (HAE) attacks.
As an expectorant.For the symptomatic treatment of acute exacerbations of chronic bronchitis in adults.